Today, the efforts of Accelerate Brain Cancer Cure (ABC2) and its partners are laying the groundwork for significant medical advances. ABC2 applies a core principle found in the for-profit business world, collaboration, to break-down the silos that often limit the efforts of medical/academia, industry and the government.

ABC2 uses its unique position to bring-together leaders in their respective fields to explore novel research that will speed new treatments to patients. Our initiatives are focused on bringing hope to often overlooked areas of translational research.

ABC2 Clinical Network - The ABC2 Clinical Network serves as a resource to patients and the scientific and medical communities. Members include the Preston Robert Tisch Brain Tumor Center at Duke University, the M.D. Anderson Cancer Center, the University of California-Los Angeles, and the University of California-San Francisco.

Preclinical Screening Program - ABC2 and the Preston Robert Tisch Brain Tumor Center at Duke University have formed the Preclinical Screening Program, a groundbreaking collaboration that establishes a critical missing link between the biopharmaceutical industry’s efforts to produce potentially life-saving drugs and the still theoretical knowledge at the cutting edge of scientific inquiry.

Industry Collaborations - ABC2’s partnerships with two leading biotechnology companies, Genentech, Inc, and CombinatoRX, push new drug therapies into the clinic for the benefit of brain cancer patients.